Published online before print June 30, 2008, doi: 10.1161/HYPERTENSIONAHA.108.111054
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2008;52:222.)
© 2008 American Heart Association, Inc.
Original Articles |
Efficacy and Safety of the Angiotensin Receptor Blocker Valsartan in Children With Hypertension Aged 1 to 5 Years
From the Division of Nephrology (J.T.F.), Children’s Hospital and Regional Medical Center, Seattle, Wash; Division of Nephrology (K.E.C.M.), Children’s Hospital of Philadelphia, Pa; Department of Pediatrics (J.P.N.), Instituto Materno Infantil de Pernambuco, Recife, Pernambuco, Brazil; Centro de Nefrolog Ped do Parana-Hosp (R.d.P.M.), Curitibal, Brazil; Department of Pediatric and Adolescent Nephrology and Hypertension (A.Z.), Gdansk University Medical School, Gdansk, Poland; Department of Pediatrics (A.B.), All India Institute of Medical Sciences, New Delhi, India; Zuid Afrikaanse Hospital (L.M.), Muckleneuk, South Africa; and Cardiovascular Research (V.S., J.G., S.S-Y., G.H.), Novartis Pharmaceuticals Corporation, East Hanover, NJ.
Correspondence to Joseph T. Flynn, Division of Nephrology, A-7931, Children’s Hospital and Regional Medical Center, 4800 Sand Point Way NE, Seattle, WA 98105. E-mail joseph.flynn{at}seattlechildrens.org
The efficacy and safety of valsartan were studied in 90 children (mean age: 3.2 years; 60% male; 30% black) with systolic blood pressure (SBP) 
95th percentile. Nineteen percent received valsartan in addition to previous antihypertensive therapy. Subjects were randomly assigned to low-, medium-, or high-dose valsartan for 2 weeks (phase 1) and then reassigned randomly to placebo or to remain on the same valsartan dose for 2 additional weeks (phase 2). After this, subjects were enrolled into a 52-week, open-label phase during which valsartan was dosed to achieve SBP <95th percentile. Statistically significant reductions in SBP and diastolic blood pressure of 
8.5 mm Hg and 5.7 mm Hg, respectively, were observed at the end of phase 1 in all of the valsartan dose groups. SBP and diastolic blood pressure were also significantly lower during phase 2 in valsartan recipients compared with placebo recipients. SBP <95th percentile was achieved in 77.3% of subjects during the open-label phase. Adverse events were minor and occurred at similar frequencies in each of the 3 dose groups in phase 1 and at equal frequencies in the valsartan and placebo arms in phase 2. Serious adverse events and drug-related adverse events occurred infrequently during both the double-blind (2.2% and 5.6%, respectively) and open-label (14.8% and 6.8%, respectively) portions of the study. Valsartan treatment had no demonstrable negative effects on growth and development. In this study, the first trial of an antihypertensive agent conducted in children <6 years of age, valsartan effectively lowered SBP and diastolic blood pressure compared with placebo.
Key Words: children • kidney disease • hypertension • valsartan • angiotensin receptor blocker • clinical trial
Related Article:
Hypertension 2008 52: 201-202.
This article has been cited by other articles:
 |
|
 |
|
  J. T. Flynn Hypertension in the young: epidemiology, sequelae and therapy Nephrol. Dial. Transplant., November 7, 2008; (2008) gfn597v1. [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Sinaiko Antihypertensive Therapy in Children: Implications for Future Studies Hypertension, August 1, 2008; 52(2): 201 - 202. [Full Text] [PDF]
|
|